显微血尿:AUA/SUFU 指南
PURPOSE: Patients presenting with microhematuria represent a heterogeneous population with a broad spectrum of risk for genitourinary malignancy.…
要点
- 显微血尿定义为单次镜检每高倍视野≥3 个红细胞。
- 按年龄、性别、吸烟等风险因素分为低、中、高危三层。
- 依风险决定膀胱镜和上尿路影像,并共享决策。
核心结论
- 显微血尿患者应按泌尿生殖系恶性肿瘤风险分层,并采用基于风险的诊断策略。
研究设计与样本
- 由专家小组制定循证陈述,陈述类型关联证据强度、确定性水平及利弊判断。
主要发现
- 显微血尿应定义为单次尿沉渣镜检每高倍视野≥3 个红细胞。
- 妇科或非恶性泌尿系来源者应在病因解决后复查尿常规。
- 风险分层依据年龄、性别、吸烟及其他尿路上皮癌风险因素、显微血尿程度与持续性及既往肉眼血尿。
关键数值与推荐
- 显微血尿定义:单次镜检每高倍视野≥3 个红细胞。
- 按风险推荐膀胱镜与上尿路影像,并涉及共享决策。
- 指南陈述亦涵盖显微血尿评估阴性后的随访。
临床怎么用
- 先确认显微血尿定义并排除妇科或非恶性泌尿系来源后复查。
- 按低、中、高危分层选择膀胱镜和上尿路影像并共享决策。
- 评估阴性后按指南陈述进行随访。
局限性
- 需未来高质量研究改善此类患者诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients presenting with microhematuria represent a heterogeneous population with a broad spectrum of risk for genitourinary malignancy. Recognizing that patient-specific characteristics modify the risk of underlying malignant etiologies, this guideline sought to provide a personalized diagnostic testing strategy. MATERIALS AND METHODS: The systematic review incorporated evidence published from January 2010 through February 2019, with an updated literature search to include studies published up to December 2019. Evidence-based statements were developed by the expert Panel, with statement type linked to evidence strength, level of certainty, and the Panel's judgment regarding the balance between benefits and risks/burdens. RESULTS: Microhematuria should be defined as ≥ 3 red blood cells per high power field on microscopic evaluation of a single specimen. In patients diagnosed with gynecologic or non-malignant genitourinary sources of microhematuria, clinicians should repeat urinalysis following resolution of the gynecologic or non-malignant genitourinary cause. The Panel created a risk classification system for patients with microhematuria, stratified as low-, intermediate-, or high-risk for genitourinary malignancy. Risk groups were based on factors including age, sex, smoking and other urothelial cancer risk factors, degree and persistence of microhematuria, as well as prior gross hematuria. Diagnostic evaluation with cystoscopy and upper tract imaging was recommended according to patient risk and involving shared decision-making. Statements also inform follow-up after a negative microhematuria evaluation. CONCLUSIONS: Patients with microhematuria should be classified based on their risk of genitourinary malignancy and evaluated with a risk-based strategy. Future high-quality studies are required to improve the care of these patients.
引用
- Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020. PMID: 32698717. doi:10.1097/JU.0000000000001297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。